Author index

C. Abad, 557
J. Acar, 1, 477
D. Acosta, 391
L. Adam, 251
I. Adamsson, 175, 265
A. Adler, 220
H. E. Agel, 561
N. Aggarwal, 88
P. Aguiar, 149
D. Ainouz, 316
R. Aitmhand, 48
A. Akbulut, 111
A. K. Al Jardani, 173
S. Al Mahmood, 137
F. M. Al Yaqubi, 173
W. A. Al-Baker, 218
S. Alcaraz García, 226
A. Alejo, 268
A. I. Aller García, 226
A. G. Allum, 19
J. I. Alós, 273
H. Al-Sayer, 94
A. Alvarez, 169
F. Alvarez, 643
Ö. Anğ, 593
M. Anğ-Küçüker, 593
F. Antunes, 149
N. Apostolopoulos, 69
B. Aracil, 273
J. P. Arends, 53
L. Arreaza, 229
J. Aspa, 543
J. Astudillo, 263
H. Aubry-Damon, 59
R. Auckenthaler, 608
E. Aydin, 561
S. Aytekin, 617
A. Ayyildiz, 327, 341, 617

F. Ba, 363
P. Bailly, 376
R. M. Bannatyne, 137
C. Bardin, 117
P. Barreiro, 152, 621
C. Barros, 643
A. L. Barry, 285, 500
A. L. Barth, 178
A. Bartoloni, 170, 568
A. Barzilai, 677
R. Bax, 324
G. Beaucaire, 357
N. J. Beeching, 401, 432
L. Bélec, 56, 284
M. Benbachir, 48
B. Beneda, 656
J. Bensch, 683
S. Berg, 9
K. A. Bergman, 53
X. Bertrand, 376, 519
D. J. Biedenbach, 2
J. Biggerstaff, 303
M. S. Bilal, 341
S. Bilal, 327
J. Bille, 405, 536
K. M. Bindayna, 218
J. Blahova, 103
J. R. Blanco, 566
P. Boiron, 94
J. Bomfim-Loogna, 496
E. Bonnet, 57
M. Bonten, 41, 99
L. K. Borysiewicz, 432
G. Bou, 635
R. Bou, 279
E. Bouza, 289
L. Boyanova, 622
C. S. Boye, 363
C. Branger, 316
J. Bring, 74
S. L. A. M. Bronzwaer, 59
S. D. Brown, 285, 500
N. Bruinsma, 202
J. Brun, 283
Y. Brun, 239
R. Bruno, 246
B. Bruun, 625
A. Bryskier, 660
V. Buendia, 543
M. I. Buonomini, 170
A. Burnens, 536
Ö. Büyükbaba-Boral, 593

N. Cabello, 152
H. Çakan, 327, 341
L. Caldeira, 149
S. M. Callister, 368
J. Carlet, 442
E. D. Carrol, 259
P. Casassus, 334
M. Casewell, 477
A. Castelo, 34
A. Castillo, 142
D. A. Caugant, 290
A. Cedrés, 560
E. Cercenado, 517
C. Cerveró, 635
R. Cevenini, 164
W. Chamberlin, 303
I. Chambers, 619
R. Chandy, 94
F. Chast, 117
S. Chatzipanagiotou, 157
I. Cherta, 115
E.-W. Chew, 277
M. Chodorowska, 50
B. A. Claesson, 9
M. C. Claros, 600
J. Cobo, 643
J. Cohen, 449
J. E. Coia, 125
A. Collignon, 154
E. Condes, 643
E. M. Cooke, 408
M. Corachán, 557
G. Corti, 170
P. Courvalin, 608
I. A. Critchley, 178
M. A. T. Croco, 103
C. L. Croke, 368
M. J. Crowe, 277
P. Cruaud, 154
E. Cuchí, 115
M. Cuenca-Estrella, 543
B. A. Cunha, 207, 270, 633
C. B. Cunha, 270
C. Cuny, 331
L. Cuzin, 57

A. Dalsgaard, 625
H. Damaskopoulou, 652
C. Darras-Joly, 284
T. Das Chugh, 94
B. C. Das, 88
A. De Alarcón, 391
A. J. De Neeling, 59
D. De Orsi, 164
F. De Ory, 64
L. Debaisieux, 213
M. Debiaggi, 246
D. J. Decoster, 368
J. E. Degener, 59
F. Delisle, 131
V. Deliyianni, 69, 287
K. Demirdağ, 111
C. Demiroğlu, 617
M. Denton, 397
A. Deplano, 239
L. Diamantstein, 677
T. M. Diaz-Guerra, 543
A. Digranes, 19
L. Dijkshoorn, 82
M. Dolina, 395
P. Domenico, 270
À. Domínguez, 279
M. A. Domínguez, 635
M. Donati, 164
E. Draghijeva, 328
U. B. Dragsted, 167
G. L. Drusano, 185
M. J. Dupont, 519
B. Durmaz, 561

J. M. Echevarría, 64
C. Edlund, 158, 175, 265
J. R. Edwards, 185
M. V. Eidelstain, 103
K. M. Elhag, 173
Z. Elias, 57
N. Elmdaghri, 48
S. Emler, 568
L. Engstrand, 265
J. M. Estavoyer, 519

C. Féger, 608
S. Felek, 111
J. M. Fellick, 259
F. Fernández, 385
P. Féron, 316

© 2000 Copyright by the European Society of Clinical Microbiology and Infectious Diseases

Author index

C. Abad, 557
J. Acar, 1, 477
D. Acosta, 391
L. Adam, 251
I. Adamsson, 175, 265
A. Adler, 220
H. E. Agel, 561
N. Aggarwal, 88
P. Aguiar, 149
D. Ainouz, 316
R. Aitmhand, 48
A. Akbulut, 111
A. K. Al Jardani, 173
S. Al Mahmood, 137
F. M. Al Yaqubi, 173
W. A. Al-Baker, 218
S. Alcaraz García, 226
A. Alejo, 268
A. I. Aller García, 226
A. G. Allum, 19
J. I. Alós, 273
H. Al-Sayer, 94
A. Alvarez, 169
F. Alvarez, 643
Ö. Anğ, 593
M. Anğ-Küçüker, 593
F. Antunes, 149
N. Apostolopoulos, 69
B. Aracil, 273
J. P. Arends, 53
L. Arreaza, 229
J. Aspa, 543
J. Astudillo, 263
H. Aubry-Damon, 59
R. Auckenthaler, 608
E. Aydin, 561
S. Aytekin, 617
A. Ayyildiz, 327, 341, 617

F. Ba, 363
P. Bailly, 376
R. M. Bannatyne, 137
C. Bardin, 117
P. Barreiro, 152, 621
C. Barros, 643
A. L. Barry, 285, 500
A. L. Barth, 178
A. Bartoloni, 170, 568
A. Barzilai, 677
R. Bax, 324
G. Beaucaire, 357
N. J. Beeching, 401, 432
L. Bélec, 56, 284
M. Benbachir, 48
B. Beneda, 656
J. Bensch, 683
S. Berg, 9
K. A. Bergman, 53
X. Bertrand, 376, 519
D. J. Biedenbach, 2
J. Biggerstaff, 303
M. S. Bilal, 341
S. Bilal, 327
J. Bille, 405, 536
K. M. Bindayna, 218
J. Blahova, 103
J. R. Blanco, 566
P. Boiron, 94
J. Bomfim-Loogna, 496
E. Bonnet, 57
M. Bonten, 41, 99
L. K. Borysiewicz, 432
G. Bou, 635
R. Bou, 279
E. Bouza, 289
L. Boyanova, 622
C. S. Boye, 363
C. Branger, 316
J. Bring, 74
S. L. A. M. Bronzwaer, 59
S. D. Brown, 285, 500
N. Bruinsma, 202
J. Brun, 283
Y. Brun, 239
R. Bruno, 246
B. Bruun, 625
A. Bryskier, 660
V. Buendia, 543
M. I. Buonomini, 170
A. Burnens, 536
Ö. Büyükbaba-Boral, 593

N. Cabello, 152
H. Çakan, 327, 341
L. Caldeira, 149
S. M. Callister, 368
J. Carlet, 442
E. D. Carrol, 259
P. Casassus, 334
M. Casewell, 477
A. Castelo, 34
A. Castillo, 142
D. A. Caugant, 290
A. Cedrés, 560
E. Cercenado, 517
C. Cerveró, 635
R. Cevenini, 164
W. Chamberlin, 303
I. Chambers, 619
R. Chandy, 94
F. Chast, 117
S. Chatzipanagiotou, 157
I. Cherta, 115
E.-W. Chew, 277
M. Chodorowska, 50
B. A. Claesson, 9
M. C. Claros, 600
J. Cobo, 643
J. Cohen, 449
J. E. Coia, 125
A. Collignon, 154
E. Condes, 643
E. M. Cooke, 408
M. Corachán, 557
G. Corti, 170
P. Courvalin, 608
I. A. Critchley, 178
M. A. T. Croco, 103
C. L. Croke, 368
M. J. Crowe, 277
P. Cruaud, 154
E. Cuchí, 115
M. Cuenca-Estrella, 543
B. A. Cunha, 207, 270, 633
C. B. Cunha, 270
C. Cuny, 331
L. Cuzin, 57

A. Dalsgaard, 625
H. Damaskopoulou, 652
C. Darras-Joly, 284
T. Das Chugh, 94
B. C. Das, 88
A. De Alarcón, 391
A. J. De Neeling, 59
D. De Orsi, 164
F. De Ory, 64
L. Debaisieux, 213
M. Debiaggi, 246
D. J. Decoster, 368
J. E. Degener, 59
F. Delisle, 131
V. Deliyianni, 69, 287
K. Demirdağ, 111
C. Demiroğlu, 617
M. Denton, 397
A. Deplano, 239
L. Diamantstein, 677
T. M. Diaz-Guerra, 543
A. Digranes, 19
L. Dijkshoorn, 82
M. Dolina, 395
P. Domenico, 270
À. Domínguez, 279
M. A. Domínguez, 635
M. Donati, 164
E. Draghijeva, 328
U. B. Dragsted, 167
G. L. Drusano, 185
M. J. Dupont, 519
B. Durmaz, 561

J. M. Echevarría, 64
C. Edlund, 158, 175, 265
J. R. Edwards, 185
M. V. Eidelstain, 103
K. M. Elhag, 173
Z. Elias, 57
N. Elmdaghri, 48
S. Emler, 568
L. Engstrand, 265
J. M. Estavoyer, 519

C. Féger, 608
S. Felek, 111
J. M. Fellick, 259
F. Fernández, 385
P. Féron, 316

© 2000 Copyright by the European Society of Clinical Microbiology and Infectious Diseases

S. Ferranti, 688
D. B. Fett, 368
G. Filice, 246
R. Finch, 401
H. Fiolet, 41, 99
E. Firre, 585
D. Fontanals, 279
A. Forslund, 625
M. Forte, 149
J. Fortún, 643
P. Francioli, 536
K. Fransen, 213
J. Freeman, 477
P. C. Frei, 629
P. Frenaux, 334
C. Friis, 477
L. O. Frøholm, 290
D. A. Fuchs-Ertman, 337
G. Funke, 525

F. Gabbay, 324
A. Gairard, 117
J. M. D. Galama, 630
J.-O. Galdbart, 316
J. Galindo, 168
V. Gallais, 334
R. Galligani, 170
J. Garau, 115, 169
M. L. García, 268
C. Garzelli, 568
D. A. W. D. Gavilanes, 202
A. Gaye-Diallo, 363
K. Georgilis, 147
L. Gerace, 246
G. Gerbaud, 131
M. Gielen, 630
T. A. Gillespie, 125
J. Gilquin, 117
R. Goering, 549
W. Goettsch, 59
F. W. Goldstein, 231
J. L. Gómez-Garcés, 273
J. Gómez-Vera, 391
M. Gomis, 575
J. Gonzalez, 557
M. A. Gonzalez-Fernandez, 560
J. González-Lahoz, 152, 621
H. Goossens, 477
V. Gopalkrishna, 88
B. Gordts, 585
G. Goscinski, 74
F. K. Gould, 619
I. M. Gould, 442, 669
G. C. Gray, 2
G. Grésenguet, 56
G. Greub, 629
H. Grundmann, 438
G. Gruzman, 677
R. Gryko, 227
A. Gueye-Nydiaye, 363
N. Guiso, 131
Fuat, Gürkan, 286
J. Gutiérrez, 142

E. Habte-Gabr, 55
I. Hagege, 131
M. J. Hall, 397
D. S. Hansen, 233
M. F. Hanson, 125
R. Hare, 549
C. A. Hart, 259
S. Harthug, 19
S. Haupt, 600
R. Helmuth, 593
A. Hermoso, 142
M. J. H. M. Herpers, 202
A. Hesselbjerg, 625
M. L. Hickey, 178
J. Hobstová, 656
H. Hof, 683
E. A. Høiby, 290
R. J. Hollis, 103
E. Holst, 195
M. Holub, 656
O. Hope, 19
I. Hužička, 656
S. Hugonnet, 350
R. Husfeld, 251

M. Jäggli, 395
M. E. Jiménez-Mejías, 391
P. R. E. Johnson, 125
M. Jones, 178
R. N. Jones, 2, 103
P. Jordens, 585
T. Juncosa, 279

O. Kairé, 363
A. Kalkan, 111
M. Kanellopoulou, 652
S. Karcier, 327, 341
M. D. Kazatchkine, 117
N. Keller, 677
M. Kerkhof, 53
K. G. Kerr, 397
M. Y. Khan, 137
Z. Khan, 94
N. Kim, 207
J. L. L. Kimpen, 53
J. W. Kislak, 648
Z. Klučková, 656
J. A. J. W. Kluytmans, 410
B. Kocazeybek, 327, 341, 617
R. J. Koerner, 619
S. Kõljalg, 674
R. V. Koranne, 88
S. J. Korn, 563
E. Kostis, 147
G. Kouppari, 69, 287, 325, 340
H. P. Kourea, 337
P. Kragsbjerg, 496
M.-J. Krending, 536
B. E. Kristiansen, 19
G. Kronvall, 195, 483
S. Küçükoğlu, 327, 341
D. Kuklińska, 50
A. M. Kyriakopoulos, 490
Z. Kyriazi, 157

B. La Scola, 334
V. J. Labombardi, 648
T. Lagergård, 9
N. Lambert-Zechovsky, 316
R. Lampidis, 683
N. Langeland, 19
K. M. Lantero, 566
N. Lari, 568
C. Latorre, 279
S. Lauwers, 213
F. Lavinia, 568
J. M. Lazar, 207
R. Leclercq, 283
T. M. Leegaard, 290
N. J. Legakis, 69, 157, 490
J. M. Legg, 619
J.-C. Legrand, 585
F. Lémann, 316
J. Lemozy, 57
J. Leroy, 519
P. A. Lerwick, 337
W. Liao, 207
Liébana, 142
T. Lietz, 600
J. M. Littlewood, 397
E. Lobera, 279
A. Lobovská, 656
H. Lode, 185
J. López Cepero, 226
J. López, 64
I. López-Miragaya, 687
M. D. López-Prieto, 226
O. Lortholary, 284, 334
C. Loupa, 325, 340
A. Y. Lui, 648
B. Lundgren, 149
M. Lundholm, 74

H. M. E. Maas, 82
F. M. MacKenzie, 669
E. A. Macondo, 363
C. R. Madeley, 344
J. Maertens, 585
N. Maggi-Solcà, 38
M. W. Mah, 137
M. Maimets, 674
J.-L. Mainardi, 334
A. Makri, 652
H. Malamou-Lada, 652
B. Malbruny, 283
W. Malek, 227
V. L. Malhotra, 88
P. W. G. Mallon, 277
R. Manfredi, 579
K. Mansinho, 149
A. Mantella, 568
B. Maraha, 41, 99
M. N. Marangos, 337
B. Marchou, 57
N. Margall, 279
E. Marinis, 490
D. Marissens, 213
S. J. Marshall, 413
L. Martín-Carbonero, 621
J. Martínez Lacasa, 169
J. Martínez-Beltrán, 635
A. Martínez-Vidal, 643
P. Massip, 57
M. A. Mateo, 64
O. Matos, 149
P. Matsiota-Bernard, 223, 490
P. Mayaud, 56
M. Mazzucco, 246

© 2000 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, *CMI*, 6, 694–697

F.-X. Mbopi Kéou, 56
S. Mboup, 363
R. B. McClurg, 277
M. McKendrick, 419
F. Méan, 536
I. M. Medeiros, 34
J. F. G. M. Meis, 336
E. Melcon, 643
J. Meletiadis, 336
E. Mellado, 543
Z. A. Memish, 137
C. Mendes, 178
F. Menichetti, 688
F. Mermet, 519
M. A. Meseguer, 168
F. Messina, 688
F. Mestre, 233
K. J. Meurer, 337
C. J. Miedema, 53
B. C. Millar, 277
K. Miller, 213
T. Z. Minchev, 622
B. Minderhoud, 82
V. Minnaganti, 207
I. Mitov, 622
A. Mittal, 88
J. M. Mòdol, 263
V. P. Mohan, 88
N. Mohsin, 173
C. Monzón-Moreno, 560
J. E. Moore, 277, 399
J. D. Mosquera, 566
S. B. Mossad, 559
N. Moustaoui, 48
J. W. Mouton, 336
C. Muñoz, 279
B. Mulin, 376
F.-M. Müller, 220
E. L. Munson, 368
P. G. Murphy, 277, 399
G. Muyldermans, 213

P. Naaber, 675
N. Naser, 303
S. A. Naser, 303
D. Nathwani, 387, 464
B. Nemet, 121
J.-C. Nguyen Van, 231
M.-H. Nicolas-Chanoine, 423
I. Nilsson-Ehle, 416
E. Njamkepo, 131
C. E. Nord, 158, 175, 549
J. A. Nord, 648
A. W. Notman, 125

H. O'Malley, 399
I. Odenholt, 74
M. Ojeda-Vargas, 560
A. Olazabal, 263
A. Oliver, 168
B. Olsson-Liljequist, 59
E. L. C. Ong, 14, 564
A. Ordu, 327, 341
F. A. Orrett, 45
D. Osmanliev, 622
J. Oteo, 273
U. Över, 681
M. Özdemirli, 617

J. C. Palomares, 268
H. Papadaki, 325, 340
J. Papadatos, 287
F. Paradisi, 170
D. L. Paterson, 460
M. Pauriah, 14
P. Pedersen, 167
M. L. Pedro-Botet, 263
R. Peduzzi, 395
C. Pelaz, 64
E. J. Perea, 268
C. Pérez-Martínez, 643
J. A. Pérez-Molina, 385
R. Pericas, 279
M. Perini, 246
R. Peromingo, 168
V. Petrocheilou-Paschou, 147
D. Petrov, 622
S. Petrov, 622
M. A. Pfaller, 103
I. Phillips, 324, 401
G. Piazza, 178
J.-C., Piffaretti, 38
C. Piketty, 117
V. Pineda, 279
M. D. Pinheiro, 171
C. Piromalli, 303
A. Pistorio, 246
D. Pittet, 350
I. Poilane, 154
L. Poli, 164
R. Poma, 246
I. Pons, 279
J. Pražák, 656
D. Prados, 391
J.-N. Prévost, 283
E. Prieto, 543
H. Prifti, 147
F. Provost, 94
I. Pujol, 168
S. D. Putnam, 2
A. Pütsepp, 674

C. Quereda, 635

W. Rabsch, 593
F. Raffaldi, 246
K. Rahal, 108
N. Ramdani-Bouguessa, 108
L. Ranucci, 164
S. M. Raufi, 563
S. Reed, 34
G. K. Reshedko, 103
M. M. Ribeiro, 171
F. A. I. Riordan, 259
C. Roberts, 435
G. Roche, 608
A. C. Rodloff, 600
A. Rodríguez, 687
J.-L. Rodriguez-Tudela, 543
C. Romero, 303
D. Romero, 560
E. Romero, 246
J. Romero, 268
E. J. K. Rosenthal, 563
F. F. Rossi, 178
P. Rossier, 536
S. Rubiano, 142
B. Rubinovitch, 677
E. Rubinstein, 678
M. Ruhnke, 220
J. Ruiz-Galiana, 643

J. Sabán, 168
F. Sabatelli, 549
M. Sabria, 263
P. Sacchi, 246
H. S. Sader, 178
L. Saez, 169
D. F. Sahm, 178
L. Sailler, 57
H. Salih, 251
R. Salomão, 34
V. Sambri, 164
B. Sánchez, 575
F. Sánchez, 279
I. Sanfeliu, 279
K. Şarman, 617
G. Saroglou, 325, 340
R. F. Schell, 368
R. Schille, 600
R. Schuurman, 213
D. Schwartz, 303
F. Scopetti, 170
G. M. Scott, 402
R. A. Seaton, 387
I. Sechter, 233
R. Seensalu, 265
D. Şener, 327, 341, 617
R. J. Seward, 29
I. Shafran, 303
P. M. Shah, 563
P. Shears, 259
C. Sierra, 643
J. A. Sills, 259
C. Sinaniotis, 287
N. Singh, 453
J. Sjölin, 74
V. Skandami, 287
R. Smithson, 399
B. M. Sobieszczañska, 227
B. Söderquist, 496
C. O. Solberg, 428
B. Sönmez, 327, 341, 617
E. Sönmez, 561
N. Sopena, 263
V. Soriano, 152, 621
G. Söyletir, 681
F. B. Spencker, 600
M. J. W. Sprenger, 59
S. Stamatelopoulos, 147
G. Stamos, 69, 287
T. Stanley, 399
O. Stetsiouk, 103
E. E. Stobberingh, 41, 99, 202
I. Stock, 525
L. Stratchounski, 103
M. J. Struelens, 239, 585, 669
S. Susever, 593

D. Talon, 376, 519
E. Tamm, 674
C. Tascini, 688

© 2000 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, *CMI,* 6, 694–697

P. T. Tassios, 157, 490
N. C. Tauré-Kane, 363
L. M. Teixeira, 178
A. Téllez, 64
D. Terragó, 168
E. Terrero, 268
H. Thaker, 564
A. P. J. Thomson, 259
C. Thornsberry, 178
M. Thouverez, 376, 519
T. T. Titus, 619
N. J. Todd, 397
V. Tolun, 593
J. C. Torlotin, 154
E. Törnqvist, 496
J. Torres, 687
M. J. Torres, 268
E. Tortoli, 568
D. Törümküney-Akbulut, 593
J. Tost, 169
K. J. Towner, 29
E. Trikka-Graphakos, 157
A. Trilla, 557
B. Trollfors, 9
R. Troxler, 525
Y. Tüç, 681
A. Tucci, 164
G. S. Turett, 648
R. Türköz, 561
S. Tyski, 50

E. Ural, 327, 341
E. Urfer, 536
I. Usunova, 622

D. Vaira, 213
A. J. Valenti, 337
C. Valsangiacomo, 38, 395
J. Van De Ven, 308
P. J. Van Den Broek, 413
J. M. W. Van Der Meer, 426, 669
J. Van Eldere, 308, 445
W. J. Van Leeuwen, 239
E. Van Oorschot, 82
A.-M. Vandamme, 213
A.-T. Vandenbroucke, 213
F. J. Vasallo, 688
J. A. Vázquez, 229
R. M. Vena, 368
N. Verbiest, 308
L. Verbist, 308
M. Vergnaud, 283
J. Verhaegen, 308
C. Verhofstede, 213
C. Verwaest, 294
P. E. Verweij, 336
P. Viciana, 391
J. R. Villagrasa, 543
J. S. H. Vles, 202
L. Vogel, 82
A. Von Graevenitz, 525
C. Von Hunolstein, 170
A. Voss, 410
D. Voyatzoglou, 325, 340
G. Vrioni, 223

M. C. J. Wale, 59
W. Walsh, 55
S. Walter, 600
S. Waser, 223
B. J. Weber, 202
C. M. R. Weemaes, 630
K. Weist, 438
B. Wiedemann, 525
R. Wilkinson, 619
A. Willke, 687
P. L. Winokur, 103
W. Witte, 239, 331

G. Yoseph, 677

M. Zabalza, 566
G. Zackrisson, 9
Ž. Žagar, 121
N. Zakopoulos, 147
J.-J. Zambrowski, 464
A. Zaphiropoulou, 69, 287
F. Zara, 246
S. H. Zimmerman, 337
G. Zissis, 213
A. Zwahlen, 536

© 2000 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, *CMI*, 6, 694–697

Subject Index

Abacavir, tolerability (concise communication), 621
Abscess
  liver, due to *Listeria monocytogenes* (correspondence), 226
  psoas, pneumococcal (correspondence), 168
  skin, cardiac failure and (continuing medical education), 557
ABT 773 660
Acinetobacter sp., molecular identification in patient with culture-negative endocarditis (concise communication), 277
Acinetobacter baumannii, multiresistant nosocomial outbreak, characterization by REP-PCR and AP-PCR, 635
Acquired immune deficiency syndrome *see* AIDS
Actinobacillus actinomycetemcomitans endocarditis, oxfloxacin treatment (correspondence), 55
Adult respiratory distress syndrome, as complication of postanginal sepsis (correspondence), 337
Agammaglobulinemia, enterovirus antibody titers after IVIG replacement (correspondence), 630
Agar dilution method, *Clostridium difficile* antimicrobial susceptibility testing (concise communication), 154
AIDS
  cytomegalovirus retinitis and 14
    plasma levels of ganciclovir in patients receiving oral therapy, 117
  Mycobacterium avium in, 490
Amikacin, activity against multiresistant *Pseudomonas aeruginosa* (correspondence), 688
Aminoglycosides, nephrotoxicity, effect of once-daily dosing (notes and comments), 357
Ampicillin-resistant *Enterococcus faecium*, 19
Anaerobic cocci, evaluation and resistance patterns (concise communication), 619
Antibiotic therapy
  antibiotic selection in empirical therapy, S3.98
  parenteral, outpatient and home, 387, 464
  pharmacoeconomics, S3.90
  severe infections in hospitalized patients, S2.7
Antibiotics
  animal growth promotion 477
  ß-lactam
    resistance to 94, S2.2, S3.27, S3.93
    see also Cephalosporins
  clinical trials: Witley Park symposium, 324
  macrolide, in vitro activity against *Bordetella pertussis* (concise communication), 50
  prescription in general internal medical wards
    impact of microbiological cultures (concise communication), 99
    trends in (concise communication), 41
  see also names of specific antibiotics
Antifungal agents, S2.23
Antigen detection, diagnosis of meningococcal disease, 259
Antimicrobial resistance, S3.101
  European Congress of Clinical Microbiology and Infectious Diseases, satellite symposium, S2.1
  anaerobic cocci (concise communication), 619
  ß-lactams, S2.2, S3.27, S3.93
    hospital infections: role of new cephalosporins, S3.95
  community-acquired infections, S2.11
  European control strategy, 669
  extended-spectrum ß-lactamases and S2.2
  group A streptococci, 652
  Haemophilus influenzae from nasopharyngeal specimens, 519
  Staphylococcus lugdunensis (concise communication), 496
  Staphylococcus aureus from hospitalized patients and dairy food (concise communication), 395
  Streptococcus pneumoniae in outpatients (correspondence), 563
  surveillance
    respiratory pathogens, Brazil, 178
    Streptococcus pneumoniae and *Staphylococcus aureus*, within European Antimicrobial Resistance Surveillance System, 59
  see also under specific antimicrobials and organisms
Antimicrobial susceptibility
  apparent differences as a consequence of national guidelines (notes and comments), 290
  natural susceptibility of *Listeria* spp. 525
Antimicrobial susceptibility testing
  calibration of disk diffusion test for trovafloxacin susceptibility of four anaerobes, 195
  Clostridium difficile, comparison of E test and reference agar dilution method (concise communication), 154
  determination of minimum inhibitory concentrations by agar dilution (EUCAST definitive document E.Def 3.1), 509
  determination of test breakpoints (EUCAST definitive document E.DEF 2.1), 570
  methicillin-resistant staphylococci, 549
  Mycobacterium avium, 368, 648
  Mycobacterium tuberculosis, 353
  Nocardia asteroides soil isolates from Kuwait, 94
  quality control parameters for tests of *Haemophilus influenzae* against carbapenems (concise communication), 500

© 2000 Copyright by the European Society of Clinical Microbiology and Infectious Diseases

Salmonella typhimurium and *Salmonella enteritidis*, 593
Streptococcus pneumoniae, Haemophilus influenzae and *Moraxella catarrhalis* in children (concise communication), 675
terminology (EUCAST definitive document E.def 1.2), 503
Antiretroviral drugs
hyperglycemia associated with protease inhibitors (concise communication), 391
resistance to (concise communication), 268
see also HAART
Aortic valve, prosthetic, *Aspergillus niger* endocarditis (continuing medical education), 617
Aspergillosis, characterization of possible nosocomial outbreak, 543
Aspergillus niger endocarditis following aortic valve replacement (continuing medical education), 617
Avoparcin as animal growth promoter, 477
Azithromycin chemoprophylaxis, effect on streptococcal colonization rates, 2

Bacillary angiomatosis in acute leukemia (correspondence), 334
Beta-lactamases, extended-spectrum (ESBLs)
antibiotic resistance and S2.2, S2.14
expression by *Klebsiella pneumoniae* isolates (concise communication), 103
TEM-24-producing *Enterobacter aerogenes* 316
treatment of severe infections caused by Enterobacteriaceae producing ESBLs 460
Beta-lactams *see* Antibiotics, ß-lactam; Cephalosporins
Bordetella bronchiseptica bronchitis (concise communication), 147
Bordetella holmesii from sickle cell anemia patient, comparison with other isolates, 131
Bordetella pertussis, in vitro activity of macrolides against (concise communication), 50
Bradycardia, relative, diagnostic significance (editorial), 633
Bronchitis, *Bordetella bronchiseptica* (concise communication), 147
Brotzu, Giuseppe, S3.3, S3.6, S3.9
Brucella endocarditis (continuing medical education), 327, 341
Brucellosis, experimental murine, therapeutic effects of rifampin and erythromycin (concise communication), 111

CagA enxyme-linked immunosorbent assay, *Helicobacter pylori* diagnosis (concise communication), 164
Campylobacter spp., food poisoning outbreak in Northern Ireland (concise communication), 399
Candida albicans, fluconazole-resistant, clearance after switching antifungal therapy and initiation of triple therapy for HIV (concise communication), 220
Carbapenems
Haemophilus influenzae susceptibility tests, quality control parameters (concise communication), 500
severe infections caused by Enterobacteriaceae producing extended-spectrum ß-lactamases, 460
Cardiac tuberculosis (continuing medical education), 557
Catheter-related infection
fibronectin concentrations in catheter sepsis, 121
Serratia liquefaciens (concise communication), 559
subcutaneous ventricular infections in preterm infants and young children, 203
Cefixime, community-acquired infections, S3.79
Cefotaxime disk susceptibility, revision of quality control limits (correspondence), 285
Cefoxitin resistance, anaerobic cocci (concise communication), 619
Cefuroxime induction of endotoxin release, effect of tobramycin, 74
Cephalosporins
classification, S3.13
development, S3.10, S3.13
discovery, S3.6
Gram-negative activity, S3.22
long-acting, lower respiratory tract infections, S3.87
microbiological update, S3.41
oral
acute otitis media, S3.61
community-acquired infections, S3.64, S3.76, S3.79
pediatric infections, S3.76
pharmacokinetics, S3.53
pharyngotonsillitis, S3.59
respiratory tract infections, S3.56, S3.70
role in ambulatory medicine, S3.55
urinary tract infections, S3.73
parenteral, community acquired lower respiratory tract infections, S3.84
penicillin-binding proteins and S3.34, S3.82
pharmacoeconomics, S3.90
pharmacokinetics, S3.46
oral cephalosporins, S3.53
pharmacological update, S3.50
resistance to S3.27, S3.41
hospital infections, S3.95
respiratory tract infections
lower S3.84, S3.87
upper S3.56, S3.70
third-generation, *Enterobacter* resistance to 376
Cerebral infarct, as complication of postanginal sepsis (correspondence), 337
Cervical cancer/precancer, *Chlamydia trachomatis* and human papillomavirus infection prevalence in Indian women, 89
Cheese, antimicrobial susceptibility of *Staphylococcus aureus* from (concise communication), 395
Chlamydia trachomatis, Indian women, 88

© 2000 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, *CMI*, 6, 698–706

Cilastatin *see* Imipenem/cilastatin
Ciprofloxacin
  antibacterial activity: effect of albumin, globulin, pus and dead bacteria (concise communication), 678
  MIC determination using multidisk diffusion tests, 483
Clindamycin resistance, anaerobic cocci (concise communication), 619
Clinical microbiology
  models for change, 445
  training in UK, 435
  UK model, 402
  University Hospital of Lausanne, 405
Clostridium difficile, antimicrobial susceptibility testing, comparison of E test and reference agar dilution method (concise communication), 154
Clostridium histolyticum endocarditis (correspondence), 562
CMV *see* Cytomegalovirus
Cocci, anaerobic, evaluation and resistance patterns (concise communication), 619
Colistin, activity against multiresistant *Pseudomonas aeruginosa* (correspondence), 688
Community-acquired infections
  antimicrobial resistance, S2.11
  oral cephalosporins, S3.64
    cefixime, S3.79
    pediatric, S3.76
Continuing medical education
  Brucella endocarditis, 327, 341
  cardiac tuberculosis, 557
  Helicobacter cinaedi infection in HIV-positive patient, 613
  hemoptysis and cavitating lung lesion in young woman, 263
  Lemierre's syndrome, 325, 340
  periorbital swelling and visual loss in HIV patient, 385
Control of infection *see* Management of infection
Corynebacterium urealyticum pericarditis (correspondence), 560
Crohn's disease, *Mycobacterium avium* subsp. *paratuberculosis*, 303
Cystic fibrosis
  epidemiologic characterization of *Pseudomonas aeruginosa*, 600
  Stenotrophomonas maltophilia isolation from sputa (concise communication), 397
Cytomegalovirus (CMV) retinitis, AIDS patients, 14
  plasma levels of ganciclovir in patients receiving oral therapy 117
Cytometry, flow *see* Flow cytometry

Dairy food, antimicrobial susceptibility of *Staphylococcus aureus* from (concise communication), 395
Dalfopristin *see* Quinupristin/dalfopristin
DARAS®, sequence-specific recognition of *Neisseria meningitidis* DNA, 29
Dental caries, post-pH effect in oral streptococci, 142
Diagnostic virology, staffing (review), 344
Disk diffusion test
  calibration for trovafloxacin susceptibility testing of four anaerobic species, 195
  MIC determination of fusidic acid and ciprofloxacin using multidisk diffusion tests, 483
DNA, *Neisseria meningitidis*, sequence-specific recognition using DARAS®, 29
Doxycycline, pharmacodynamics (concise communication), 270
Dyslipidemia, management in HIV patients, 579

E test, *Clostridium difficile* antimicrobial susceptibility testing (concise communication), 154
Echocardiography, transesophageal, infective endocarditis and (correspondence), 169
Education, continuing *see* Continuing medical education
Electrophoresis, pulsed-field gel *see* Pulsed-field gel electrophoresis
Endocarditis, infective
  Actinobacillus actinomycetemcomitans, oxfloxacin treatment (correspondence), 55
  Aspergillus niger, following aortic valve replacement (continuing medical education), 617
  Clostridium histolyticum (correspondence), 562
  culture-negative, molecular identification of *Acinetobacter* sp. (concise communication), 277
  Gemella haemolysans endocarditis in hemachromatosis patient (correspondence), 566
  multi-valvular, 207
  Serratia liquefaciens catheter-related infection (concise communication), 559
  transesophageal echocardiography and antibiotic prophylaxis (correspondence), 169
  unusual cause (continuing medical education), 327, 341
Endotoxin release, cefuroxime-induced, effect of tobramycin 74
Enterobacter spp., resistance to third-generation cephalosporins, clinical and molecular epidemiology, 376
Enterobacter aerogenes, TEM-24 producing, 316
Enterobacteriaceae, ESBL-producing, treatment of severe infections, 460
Enterococci
  colonization risk factors, neonatal intensive care unit (correspondence), 53
  vancomycin-resistant, community-acquired infection, S2.13
Enterococcus faecium
  ampicillin-resistant, 19
  vancomycin-resistant, vanB type, 19
Enterovirus antibody titers after IVIG replacement in agammaglobulinemic children (correspondence), 630

© 2000 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, *CMI*, 6, 698–706

Erythromycin, effect in experimental murine brucellosis (concise communication), 111
ESBLs *see* Beta-lactamases, extended-spectrum
Escherichia coli
antibacterial activity of moxfloxacin, trovafloxacin and ciprofloxacin (concise communication), 678
children with pyelonephritis, virulence factors (concise communication), 328
epidemiologic typing, 82
verotoxigenic strains of *E.coli* 026 (correspondence), 227
ESP culture system, *Mycobacterium avium* susceptibility testing, 648
European Antimicrobial Resistance Surveillance System (EARSS), 59
Evernimicin, in vitro activity against methicillin-resistant staphylococci, 549

Fibronectin, concentrations in catheter sepsis, 121
Flow cytometry, *Mycobacterium avium* susceptibility testing, 368
Fluoroquinolones, resistance to
low-level resistance among *Salmonella* and *Shigella* (correspondence), 231, 687
Salmonella enterica: resistance to nalidixic acid as marker (concise communication), 273
Food poisoning
Campylobacter, outbreak in Northern Ireland (concise communication), 399
Salmonella braenderup gastroenteritis outbreak due to contaminated meat pies, 536
Fungal infections, need for new antifungal agents, S2.23
Fusidic acid, MIC determination using multidisk diffusion tests, 483
Fusobacterium necrophorum infections (correspondence), 337

Ganciclovir, plasma levels in AIDS patients receiving oral therapy for CMV retinitis, 117
Gastroenteritis, listeria, newborn (concise communication), 683
Gemella haemolysans endocarditis, hemachromatosis patient (correspondence), 566
Glycopeptide-intermediate *Staphylococcus aureus*
editorial, 517
Oman (correspondence), 173
Glycopeptides, guidelines for use in Belgium, 585
Gram-negative bacteria, antimicrobial resistance, S2.13
Growth promotion in animals: avoparcin and virginiamycin, 477

HAART (Highly Active Antiretroviral Therapy)
dyslipidemia and 579
Mycobacterium avium complex infection in patient on HAART (correspondence), 564
Haemophilus influenzae
antibiotic susceptibility and genotypic characterization of strains from nasopharyngeal specimens, 519
antimicrobial resistance surveillance, Brazil, 178
invasive infections in children in Casablanca, serotypes/biotypes/antimicrobial susceptibilities (concise communication), 48
meningitis (concise communication), 279, 572 (erratum)
nasopharyngeal carriage and antibacterial susceptibility in children (concise communication), 675
pharyngotonsillitis and S3.59
susceptibility tests against carbapenems, quality control parameters (concise communication), 500
Hand hygiene, 350
Helicobacter cinaedi infection in HIV-positive patient (continuing medical education), 613
Helicobacter pylori
immunoblot assay to define serum antibody patterns, 218
prevalence of resistant strains in southern Switzerland (concise communication), 38
recombinant CagA enzyme-linked immunosorbent assay and western immunoblot (concise communication), 164
treatment, impact on normal gastrointestinal flora (notes and comments), 175
treatment failure, investigation using AP-PCR and flaA-RFLP typing (concise communication), 265
Hemoptysis and cavitating lung lesion in young woman (continuing medical education), 263
Hepatitis A infection, accompanying ascites and pleural effusion in children (correspondence), 286
Hepatitis B and C co-infection (correspondence), 629
Herpes simplex virus type 2, asymptomatic shedding in African women (correspondence), 56
Herpesviruses, organ transplant recipients (review), 453
Highly Active Antiretroviral Therapy *see* HAART
HIV: quality control study for quantification of HIV type 1 RNA in plasma, 213
HIV infection
detection of resistant mutations in reverse transcriptase of HIV-1-infected children (concise communication), 268
dyslipidemia management in, 579
fluconazole-resistant *Candida albicans*, clearance after switching antifungal therapy and initiation of triple therapy for HIV (concise communication), 220
Helicobacter cinaedi infection and (continuing medical education), 613
hyperglycemia associated with protease inhibitors in HIV-1-infected patients (concise communication), 391

© 2000 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, *CMI*, 6, 698–706

Mycobacterium avium complex infection in patient on HAART (correspondence), 564
periorbital swelling and visual loss (continuing medical education), 385
transfusion-transmitted virus infection in HIV-1-seropositive patients, 246
twice-daily indinavir (concise communication), 153
HPV *see* Human papillomavirus
Human herepsviruses-6,-7 and -8, organ transplant recipients (review), 453
Human immunodeficiency virus *see* HIV
Human papillomavirus (HPV), infection, Indian women, 88
Hydrocephalus, shunt infections in preterm infants and young children, 203
Hyperglycemia associated with protease inhibitors in HIV-1-infected patients (concise communication), 391

Imipenem/cilastatin, comparison with meropenem for serious bacterial infections in intensive care unit, 294
Immunoblot assay, *Helicobacter pylori* (concise communications), 164, 218
Immunoglobulin M (IgM), *Legionella pneumophila* serogroup 1 pneumonia, 64
Indinavir, twice-daily dosing (concise communication), 152
Infection control/management *see* Management of infection
Intensive care units
infection services, 442
meropenem vs imipenem/cilastatin for serious bacterial infections, 294
neonatal, risk factors for colonization with enterococci (correspondence), 53
Iodide, treatment of cutaneous sporotrichosis (correspondence), 53

Kala-azar *see* Leismaniasis, visceral
Kaposi's sarcoma herpesvirus, 456
Ketolides, 660
Klebsiella spp.
K typing, 233
phage typing, 233
Klebsiella pneumoniae, extended-spectrum ß-lactamase expression (concise communication), 103

Legionella pneumophila
detection of *L.pneumophila* DNA in urine and serum (concise communication), 223
serogroup 1, detection of specific IgM antibody, 64
Leishmaniasis, visceral, soluble tumor necrosis factor receptor levels, 34
Lemierre's syndrome (continuing medical education), 325, 340
Leukemia, acute, consecutive bacillary angiomatosis and *Rhodococcus equi* bacteremia (correspondence), 334
Linezolid, in vitro activity against staphylococci (concise communication), 331
Listeria spp.
natural antibiotic susceptibility, 525
nosocomial gastroenteritis in newborn (concise communication), 683
Listeria monocytogenes, liver abscess (correspondence), 226
Listeriosis, neonatal, Algeria (concise communication), 108
Liver abscess due to *Listeria monocytogenes* (correspondence), 226
Lungs, cavitating lesion and hemoptysis in young woman (continuing medical education), 263
Lymphadenitis
Mycobacterium avium and 490
tuberculous, Saudi Arabia, 137
Lymphocytes, subpopulations and CD3+/DR expression in sepsis, 656

Management of infection
clinical infection services
future needs, 426
Leiden, 413
Sweden, 416
United Kingdom, 419
clinical microbiology laboratories
models for change, 445
United Kingdom, 402
University Hospital of Lausanne, 405
diagnostic services, future needs, 423
future needs
clinical services, 427
diagnostic services, 423
hospitals
intensive care units, 442
Netherlands' view, 410
United Kingdom view, 409
training in, 438, 449
Meningitis
Haemophilus influenzae (concise communication), 279, 572 (erratum)
meningococcal, diagnosis using DARAS®, 29
Meningococcal disease, increasing microbiological confirmation and changing epidemiology, 259
Meningococcus *see Neisseria meningitidis*
Meropenem
clinical response in relation to *in vitro* susceptibility, 185
comparison with imipenem/cilastatin for serious bacterial infections in intensive care units, 294
Methicillin-resistant *Staphylococcus aureus* (MRSA)
community-acquired infection, S2.11
control/treatment options, S2.17
epidemic, clonal dissemination, 239
in vitro activity of evrnimicin and selected antibiotics, 549

© 2000 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, *CMI*, 6, 698–706

in vitro activity of linezolid (concise communication), 331
Methicillin-resistant *Staphylococcus epidermis* (MRSE), S2.17
Metronidazole resistance, anaerobic cocci (concise communication), 619
Minimum inhibitory concentrations (MICs), of antibacterial agents, determination by agar dilution (EUCAST definitive document E.Def 3.1), 509
Moraxella catarrhalis
antimicrobial resistance surveillance, Brazil, 178
nasopharyngeal carriage and antibacterial susceptibility in children (concise communication), 675
Moxifloxacin, antibacterial activity: effect of albumin, globulin, pus and dead bacteria (concise communication), 678
MRSA *see* Methicillin-resistant *Staphylococcus aureus*
Music and infectious diseases, 575
Mycobacteria detection, comparison of Bactec 460TB and Bactec MGIT 960 systems (correspondence), 171
Mycobacteria Growth Indicator Tube (MGIT AST SIRE), 363
Mycobacterium avium
comparison of isolates from AIDS and HIV-negative patients, 490
infection in patient on HAART (correspondence), 564
subsp. *paratuberculosis*, Crohn's disease, 303
susceptibility testing
ESP culture system, 648
flow cytometry, 368
unusual high-performance liquid chromatography profile (correspondence), 568
Mycobacterium tuberculosis, rapid susceptibility testing, 363
Mycoplasma hominis, hematoma infection following transplant nephrectomy (concise communication), 619

Nalidixic acid resistance, *Salmonella enterica* (concise communication), 273
Nasopharyngeal carriage, *Streptococcus pneumoniae*, *Haemophilus influenzae* and *Moraxella catarrhalis* in children (concise communication), 675
Neisseria meningitidis DNA
sequence-specific recognition using DARAS®, 29
serogroup 29E, reduced susceptibility to penicillin (correspondence), 229
Neonatal intensive care units, risk factors for colonization with enterococci (correspondence), 53
Nocardia asteroides
antimicrobial susceptibility testing of soil isolates from Kuwait, 94
disseminated complex infection in immunocompromised child (correspondence), 287
Nosocomial infections
Acinetobacter baumanii, PCR-based DNA fingerprinting, 635
ampicillin-resistant *Enterococcus faecium*, 19
antibiotic therapy of severe infections, S2.7
antimicrobial resistance in, role of newer cephalosporins, S3.97
antimicrobial susceptibility of *Staphylococcus aureus* (concise communication), 395
clonal dissemination of epidemic MRSA, 239
control
Netherlands' view, 410
United Kingdom view, 408
hand hygiene and, 350
Klebsiella, phage typing, 233
listeria gastroenteritis in newborn (concise communication), 683
Pseudomonas aeruginosa, eradication of resistant strain, 125
see also Intensive care units; Methicillin-resistant *Staphylococcus aureus*

Occupational infections, invasive *Streptococcus pyogenes* in surgeon (correspondence), 170
Ofloxacin, *Actinobacillus actinomycetemcomitans* endocarditis (correspondence), 55
Otitis media, acute (AOM)
cephalosporin treatment, S3.61
pneumococcal AOM in children, 69
Outpatient and home parenteral antibiotic therapy (OHPAT) (concise communication), 387
advisory group consensus statement, 464
Oxidative burst, cytofluorometric measurement using *Staphylococcus aureus* and *Candida albicans* as target organisms, 251

Papillomavirus *see* Human papillomavirus
Penicillin
reduced susceptibility of 29E meningococci (correspondence), 229
resistance, anaerobic cocci (concise communication), 619
Penicillin-binding proteins, cephalosporins and, S3.34, S3.82
Pericarditis, *Corynebacterium urealyticum* (correspondence), 560
Phagocytes, killing, cytofluorometric measurement using *Staphylococcus aureus* and *Candida albicans* as target organisms, 251
Phagocytosis, cytofluorometric measurement using *Staphylococcus aureus* and *Candida albicans* as target organisms, 251
Pharmacokinetics of antibiotics, S3.46
cephalosporins, S3.46, S3.53
Pharyngotonsillitis, cephalosporins/*Haemophilus influenzae* infection and, S3.59
Pneumococcus *see Streptococcus pneumoniae*
Pneumocystis carinii pneumonia, immunocompromised patients, diagnosis using two nested polymerase chain reactions (concise communication), 149

© 2000 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, *CMI*, 6, 698–706

Pneumonia
Legionella pneumophila serogroup 1, detection of specific IgM antibody, 64
nosocomial, antibiotic therapy, S2.7
Pneumocystis carinii see Pneumocystis carinii pneumonia
Polymerase chain reaction (PCR)
arbitrary primed, investigation of treatment failure in *Helicobacter pylori* infection (concise communication), 265
detection of prevalence of *Chlamydia trachomatis* and HPV infection in Indian women, 88
diagnosis of meningococcal disease, 259
in combination with DARAS®, system, 29
REP-PCR and AP-PCR in characterization of multiresistant outbreak of *Acinetobacter baumannii*, 635
two nested reactions for diagnosis of *Pneumocystis carinii* pneumonia in immunocompromised patients (concise communication), 149
Polyradiculoneuritis, syphilis and, HIV-negative patient (correspondence), 284
Postanginal sepsis, cerebral infarct and adult respiratory distress syndrome and (correspondence), 337
Protease inhibitors, HIV infection
dyslipidemia and, 579
hyperglycemia and (concise communication), 391
Pseudomonas aeruginosa
epidemiologic characterization in cystic fibrosis patients, 600
eradication of resistant strain in hematology/oncology unit, 125
multiresistant (correspondence), 688
Psoas abscess, pneumococcal (correspondence), 168
Pulsed-field gel electrophoresis (PFGE)
comparison of *Mycobacterium avium* isolates fro AIDS and HIV-negative patients, 490
MRSA typing, 239
Pseudomonas aeruginosa in cystic fibrosis patients, 490
Pyelonephritis, virulence factors in *Escherichia coli* strains from children (concise communication), 328
Pyocin typing, *Pseudomonas aeruginosa* in cystic fibrosis patients, 490

Quinupristin/dalfopristin, in vitro activity against staphylococci, 608

Random amplified polymorphic DNA (RAPD) analysis
Aspergillus typing, 543
Escherichia coli typing, 82
Renal transplant: hematoma infection with *Mycoplasma hominis* following transplant nephrectomy (concise communication), 619
Resistance *see* Antimicrobial resistance
Respiratory tract infections
lower
long-acting cephalosporins, S3.87
parenteral cephalosporins in community-acquired infections, S3.84
upper, oral cephalosporins in, S3.56, S3.70
Restriction fragment length polymorphism, flaA gene, investigation of treatment failure in *Helicobactr pylori* infection (concise communication), 265
Retinitis, cytomegalovirus, AIDS patients, 14
plasma levels of ganciclovir in patients receiving oral therapy, 117
Rhodococcus equi bacteremia in acute leukemia (correspondence), 334
Ribotyping, *Escherichia coli*, 82
Rifampin
activity against multiresistant *Pseudomonas aeruginosa* (correspondence), 688
effect in experimental murine brucellosis (concise communication), 111

Salmonella spp., antibiotic resistance
community-acquired infections, S2.14
low-level resistance to fluoroquinolones (correspondence), 231, 687
Salmonella braenderup gastroenteritis outbreak due to contaminated meat pies, 536
Salmonella enterica, resistance to nalidixic acid: role as marker of resistance to fluoroquinolones (concise communication), 273
Salmonella enteritidis, phage types/antibiotic susceptibilities/plasmid profiles, 593
Salmonella typhi, multiresistant, relapse after combined ciprofloxacin and ceftriaxone therapy (correspondence), 167
Salmonella typhimurium, phage types/antibiotic susceptibilities/plasmid profiles, 593
Scedosporium prolificans, invasive infections, combination chemotherapy (correspondence), 336
Sepsis
catheter, fibronectin concentrations, 121
lymphocyte subpopulations and CD3+/DR expression, 656
postanginal, ARDS and (correspondence), 337
Serotyping, *Escherichia coli*, 82
Serratia liquefaciens, catheter-related infection (correspondence), 559
Sexually transmitted diseases (STDs), *Chlamydia trachomatis* and human papillomavirus infection prevalence in Indian women, 89
Shigella spp., low-level resistance to fluoroquinolones (correspondence), 231, 687

© 2000 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, *CMI*, 6, 698–706

Sickle cell anemia, *Bordetella holmesii* isolate from, 131
Sporotrichosis, cutaneous, iodide treatment (correspondence), 53
Staphylococci
  antibiotic-resistant, community-acquired infection, S2.12
  coagulase-negative
    catheter infections, fibronectin concentrations and, 121
    methicillin-resistant, antibiotic susceptibility, 549
  methicillin-resistant, in vitro activity of evrnimicin and selected antibiotics, 549
  in vitro activity of linezolid (concise communication), 331
  in vitro activity of quinuprostin/dalfopristin, 608
Staphylococcus aureus
  antibacterial activity of moxfloxacin, trovafloxacin and ciprofloxacin (concise communication), 678
  antimicrobial resistance surveillance within European Antimicrobial Resistance Surveillance System, 59
  antimicrobial susceptibility in isolates from hospitalized patients and dairy food (concise communication), 395
  catalase-negative (concise communication), 681
  glycopeptide-intermediate
    editorial, 517
    Oman (correspondence), 173
  methicillin-resistant *see* Methicillin-resistant *Staphyloccoccus aureus*
Staphylococcus epidermis, methicillin-resistant, S2.17
Staphylococcus lugdunensis, antimicrobial resistance to (concise communication), 496
Stenotrophomonas maltophilia, isolation from sputa of cystic fibrosis patients (concise communication), 397
Streptococci
  group A, epidemiological study in pediatric specimens in Athens, 652
  group B, serotypes and clinical manifestations, 9
  oral, post-pH effect, 142
Streptococcus pneumoniae
  acute otitis media in children, 69
  antibacterial activity of moxfloxacin, trovafloxacin and ciprofloxacin (concise communication), 678
  antimicrobial resistance, 308
    community-acquired infection, S2.13
  antimicrobial resistance surveillance
    Brazil, 178
    within European Antimicrobial Resistance Surveillance System, 59
  apparently false-positive blood cultures (correspondence), 688
  colonization rates, effect of azithromycin chemoprophylaxis, 2
  evolution of serotypes and antibiotic resistance in Belgium, 308
  isolation of strain susceptible to amoxycillin and resistant to cefotaxime (correspondence), 283
  nasopharyngeal carriage and antibacterial susceptibility in children (concise communication), 675
  psoas abscess (correspondence), 168
  susceptibility pattern in outpatients (correspondence), 563
Streptococcus pyogenes
  colonization rates, effect of azithromycin chemoprophylaxis, 2
  invasive infection in surgeon after occupational exposure (correspondence), 170
Suceptibility testing *see* Antimicrobial susceptibility testing
Sulphonamides, resistance to, *Nocardia asteroides* soil isolates, 94
Syphilis, polyradiculoneuritis in, HIV-negative patient (correspondence), 284

Teicoplanin, guidelines for use in Belgium, 585
Telithromycin, 660
Thrombophlebitis, *Serratia liquefaciens* catheter-related infection (correspondence), 559
TNF *see* Tumor necrosis factor
Tobramycin, effect on cefuroxime-induced endotoxin release, 74
Tonsillitis, cephalosporins/*Haemophilus influenzae* infection and, S3.59
Training for infection disciplines
  Britain, 432, 435
  future direction, 449
  Norway, 428
Transesophageal echocardiography (TEE), infective endocarditis and (correspondence), 169
Transfusion-transmitted virus infection in HIV-1-seropositive patients, 246
Transplant surgery
  hematoma infection with *Mycoplasma hominis* following transplant nephrectomy (concise communication), 619
  herpesvirus infections in transplant recipients (review), 453
Treponema pallidum polyradiculoneuritis, HIV-negative patient (correspondence), 284
Trovafloxacin
  antibacterial activity: effect of albumin, globulin, pus and dead bacteria (concise communication), 678
  calibration of disk diffusion test for susceptibility testing of four anaerobic species, 195
Tuberculin skin test, reactivity in health care workers in Trinidad (concise communication), 45
Tuberculosis
  cardiac (continuing medical education), 557
  extralaryngeal head and neck infection, 643
Tuberculous lymphadenitis, Saudi Arabia, 137

© 2000 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, *CMI*, 6, 698–706

Tumor necrosis factor receptors (TNFR), soluble, levels in visceral leishmaniasis, 34
Tumor necrosis factor-α (TNF-α), visceral leishmaniasis, effect of soluble tumor necrosis factor receptors, 34

Urinary tract infections, oral cephalosporins, S3.73

Vancomycin, guidelines for use in Belgium, 585
Vancomycin-resistant enterococci, community-acquired infection, S2.13
Vancomycin-resistant *Enterococcus faecium*, emerging in clonal outbreak caused by ampicillin-resistant *Enterococcus faecium*, 19
Ventriculoperitoneal drain-related infections in preterm infants and young children, 203
Vibrio cholerae non-O1 and non-O139, extra-intestinal infections (concise communication), 625
Virginiamycin as animal growth promoter, 477
Virology, diagnostic, staffing in (review), 344

Western immunoblot assay, *Helicobacter pylori* (concise communications), 164, 218

Yersinia enterocolitica, serological studies in thalassemic and nonthalassemic children (concise communication), 157

Zoonoses, as cause of fever in neutropenic patients (correspondence), 334

© 2000 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, *CMI*, 6, 698–706